Deferred Revenue

12 Months Ended

Dec. 31, 2011

10.	Deferred Revenue

Deferred revenue as of December 31, 2011 and 2010 consists of the following:

	2011	2010
Current portion:
Received from Sanofi (see Note 3a)	$20,011	$19,506
Received from Bayer HealthCare (see Note 3b)	7,907	9,884
Received for technology license agreements (see Note 4)	23,572	25,008
Other	150	325
	$51,640	$54,723

Long-term portion:
Received from Sanofi (see Note 3a)	$86,017	$97,081
Received from Bayer HealthCare (see Note 3b)	34,456	37,067
Received for technology license agreements (see Note 4)	128,137	151,708
	$248,610	$285,856

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References+ Details